Beyond bevacizumab: An outlook to new anti-angiogenics for the treatment of ovarian cancer

Frontiers in Oncology

Volumn 5, Issue OCT, 2015, Pages

  Mahner, Sven ^a,b   Woelber, Linn ^a   Mueller, Volkmar ^a   Witzel, Isabell ^a   Prieske, Katharina ^a   Grimm, Donata ^a   Amsberg, Gunhild Keller v ^a   Trillsch, Fabian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anti angiogenic therapy; Cediranib; Multikinase inhibitors; Nintedanib; Ovarian cancer; Pazopanib; Trebananib

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TOPOTECAN; TREBANANIB; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; GASTROINTESTINAL DISEASE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; LIVER TOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 84947058718     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00211     Document Type: Short Survey

References (29)

1. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 365:2473-83. doi:10.1056/NEJMoa1104390
2. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 365:2484-96. doi:10.1056/NEJMoa1103799
3. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol (2012) 30:2039-45. doi:10.1200/JCO.2012.42.0505
4. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC). J Clin Oncol (2014) 32(13):1302-8. doi:10.1200/JCO.2013.51.4489
5. Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol (2012) 30:362-71. doi:10.1200/JCO.2010.34.3178
6. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol (2014) 15:799-808. doi:10.1016/S1470-2045(14)70244-X
7. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K. Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: results from the phase III TRINOVA-1 study. J Clin Oncol (2015) 33: abtract 5503.
8. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A (2002) 99:11393-8. doi:10.1073/pnas.172398299
9. Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol (2012) 125:42-7. doi:10.1016/j.ygyno.2011.11.021
10. Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol (2012) 13:154-62. doi:10.1016/S1470-2045(11)70338-2
11. Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, et al. Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer (2014) 120:335-43. doi:10.1002/cncr.28406
12. Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs (2008) 17:253-61. doi:10.1517/13543784.17.2.253
13. Pignata S, Lorusso D, Scambia G, Sambataro D, Tamberi S, Cinieri S, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol (2015) 16:561-8. doi:10.1016/S1470-2045(15)70115-4
14. Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol (2010) 119:32-7. doi:10.1016/j.ygyno.2010.05.033
15. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol (2014) 32:3374-82. doi:10.1200/JCO.2014.55.7348
16. Ledermann JA, Hackshaw A, Kaye S, Jayson G, Gabra H, McNeish I, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol (2011) 29:3798-804. doi:10.1200/JCO.2010.33.5208
17. McCormack PL. Nintedanib: first global approval. Drugs (2015) 75:129-39. doi:10.1007/s40265-014-0335-0
18. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, et al. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-Intergroup phase III trial of standard frontline chemotherapy ± nintedanib for advanced ovarian cancer. Int J Gynecol Cancer (2013) 23:abstrLBA01.
19. Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 27:5601-6. doi:10.1200/JCO.2009.23.2777
20. Raja FA, Griffin CL, Qian W, Hirte H, Parmar MK, Swart AM, et al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer (2011) 105:884-9. doi:10.1038/bjc.2011.334
21. Ledermann JA, Perren T, Raja FA, Embleton A, Rustin GJS, Jayson G, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Eur J Cancer (2013) 49:abstrLBA10.
22. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol (2014) 15:1207-14. doi:10.1016/S1470-2045(14)70391-2
23. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9:327-37.
24. Biagi JJ, Oza AM, Chalchal HI, Grimshaw R, Ellard SL, Lee U, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol (2011) 22:335-40. doi:10.1093/annonc/mdq357
25. Baumann KH, du Bois A, Meier W, Rau J, Wimberger P, Sehouli J, et al. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy. Ann Oncol (2012) 23:2265-71. doi:10.1093/annonc/mds003
26. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 5:835-44. doi:10.1038/nrd2130
27. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol (2011) 29:69-75. doi:10.1200/JCO.2009.26.7856
28. Herzog TJ, Scambia G, Kim BG, Lhomme C, Markowska J, Ray-Coquard I, et al. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol (2013) 130:25-30. doi:10.1016/j.ygyno.2013.04.011
29. Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, et al. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. Invest New Drugs (2014) 32:729-38. doi:10.1007/s10637-014-0078-5